These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35019133)

  • 1. NEOADJUVANT CHEMORADIOTHERAPY FOLLOWED BY TRANSHITAL ESOPHAGECTOMY IN LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: IMPACT OF PATHOLOGICAL COMPLETE RESPONSE.
    Alves IPF; Tercioti Junior V; Coelho Neto JS; Ferrer JAP; Carvalheira JBC; Pereira EB; Lopes LR; Andreollo NA
    Arq Bras Cir Dig; 2022; 34(3):e1621. PubMed ID: 35019133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
    Sun HB; Xing WQ; Liu XB; Zheng Y; Yang SJ; Wang ZF; Liu SL; Ba YF; Zhang RX; Liu BX; Fan CC; Chen PN; Liang GH; Yu YK; Liu Q; Wang HR; Li HM; Li ZX;
    BMC Cancer; 2020 Apr; 20(1):303. PubMed ID: 32293362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS.
    Andreollo NA; Beraldo GC; Alves IPF; Tercioti-Junior V; Ferrer JAP; Coelho-Neto JS; Lopes LR
    Arq Bras Cir Dig; 2018 Dec; 31(4):e1405. PubMed ID: 30539980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study.
    Jiang L; Zhu J; Chen X; Wang Y; Wu L; Wan G; Han Y; Leng X; Peng L; Wang Q
    Radiat Oncol; 2022 Dec; 17(1):218. PubMed ID: 36585731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemoimmunotherapy was associated with better short-term survival of patients with locally advanced esophageal squamous cell carcinoma compared to neoadjuvant chemoradiotherapy.
    Duan X; Zhao F; Shang X; Yue J; Chen C; Ma Z; Chen Z; Zhang C; Pang Q; Zhang W; Abbas AE; Jiang H
    Cancer Med; 2024 Aug; 13(15):e70113. PubMed ID: 39136674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma.
    Blom RL; Sosef MN; Nap M; Lammering G; van den Berkmortel F; Hulshof MC; Meijer SL; Wilmink HW; van Berge Henegouwen MI
    Dis Esophagus; 2014; 27(4):380-7. PubMed ID: 24006852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
    Tang H; Wang H; Fang Y; Zhu JY; Yin J; Shen YX; Zeng ZC; Jiang DX; Hou YY; Du M; Lian CH; Zhao Q; Jiang HJ; Gong L; Li ZG; Liu J; Xie DY; Li WF; Chen C; Zheng B; Chen KN; Dai L; Liao YD; Li K; Li HC; Zhao NQ; Tan LJ
    Ann Oncol; 2023 Feb; 34(2):163-172. PubMed ID: 36400384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent radiotherapy cannot provide superiority of surgical oncological outcome and long-term survival rate in locally advanced esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy followed by minimally invasive esophagectomy.
    Wang YJ; Bao T; Li KK; Xie XF; He XD; Zhao XL; Guo W
    Surg Endosc; 2023 Sep; 37(9):7073-7082. PubMed ID: 37380741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy.
    Molena D; Sun HH; Badr AS; Mungo B; Sarkaria IS; Adusumilli PS; Bains MS; Rusch VW; Ilson DH; Rizk NP
    Dis Esophagus; 2014; 27(4):355-9. PubMed ID: 24033404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Huang TC; Lin CC; Wu YC; Chia-Hsien Cheng J; Lee JM; Wang HP; Huang PM; Hsu FM; Yeh KH; Cheng AL; Tzen KY; Hsu CH
    J Formos Med Assoc; 2019 Jun; 118(6):1024-1030. PubMed ID: 30502100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
    Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
    Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
    Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
    BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Chemoradiotherapy Using Cisplatin and 5-Fluorouracil (PF) Versus Carboplatin and Paclitaxel (CROSS Regimen) for Esophageal Squamous Cell Carcinoma (ESCC): A Propensity Score-matched Study.
    Wong IYH; Lam KO; Zhang RQ; Chan WWL; Wong CLY; Chan FSY; Kwong DLW; Law SYK
    Ann Surg; 2020 Nov; 272(5):779-785. PubMed ID: 32833766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
    Ma HB; Di ZL; Wen J; Ke Y; Sun X; Ren J
    Jpn J Clin Oncol; 2015 Feb; 45(2):169-75. PubMed ID: 25416813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma.
    Murakami Y; Hamai Y; Emi M; Hihara J; Imano N; Takeuchi Y; Takahashi I; Nishibuchi I; Kimura T; Okada M; Nagata Y
    J Radiat Res; 2018 Sep; 59(5):616-624. PubMed ID: 29939306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.